Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Nature Medicine · 2025
DOI: 10.1038/s41591-024-03431-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Medicine, 2025. Verfasst von Zhanwei Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Vaccination, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission. Using country-specific vaccine uptake rates for seasonal influenza, we found that vaccination of older adults would prevent hospitalizations by a median of 35–64% across the countries studied here. Vaccination of pregnant women could avert infant hospitalizations by 5–50%. Reductions in RSV-related mortality mirrored those estimated for hospitalizations. While substantial hospitalization costs could be averted, the impact of vaccination depends critically on uptake rates. Enhancing uptake and accessibility is crucial for maximizing the real-world impact of vaccination on reducing RSV burden among vulnerable populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
- School of Medicine, Yunnan University, Kunming, Yunnan, China.
- Laboratory of Data Discovery for Health Limited, Hong Kong Science Park, Hong Kong Special Administrative Region, China.
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
- Division of Communicable Disease Control and Prevention, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
- Public Health Emergency Management Innovation Center, Beijing, China.
Zitieren
APA
Du, Z., Pandey, A., Moghadas, S. M., Bai, Y., Wang, L., Matrajt, L., Singer, B. H., & Galvani, A. P. (2025). Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults. Nature Medicine. https://doi.org/10.1038/s41591-024-03431-7
Vancouver
Du Z, Pandey A, Moghadas SM, Bai Y, Wang L, Matrajt L, et al. Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults. Nature Medicine. 2025. doi:10.1038/s41591-024-03431-7
BibTeX
@article{Du2025,
author = {Du, Zhanwei and Pandey, Abhishek and Moghadas, Seyed M and Bai, Yuan and Wang, Lin and Matrajt, Laura and Singer, Burton H and Galvani, Alison P},
title = {Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-024-03431-7}
}
EUVIMED